Rhino Biotech Limited
Rhino Biotech Limited intends to develop plant and fungi derived nutraceuticals, and preventative and curative biopharmaceuticals. The company was formerly known as Eurasia Energy Limited and changed its name to Rhino Biotech Limited in September 2021. Rhino Biotech Limited was incorporated in 2003 and is based in South Hill, Anguilla.
Market Cap & Net Worth: Rhino Biotech Limited (RBRXF)
Rhino Biotech Limited (PINK:RBRXF) has a market capitalization of $3.10K ($3.10K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #47036 globally and #14591 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rhino Biotech Limited's stock price $0.00 by its total outstanding shares 31048400 (31.05 Million).
Rhino Biotech Limited Market Cap History: 2015 to 2024
Rhino Biotech Limited's market capitalization history from 2015 to 2024. Data shows change from $186.29K to $3.10K (-32.49% CAGR).
Rhino Biotech Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rhino Biotech Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RBRXF by Market Capitalization
Companies near Rhino Biotech Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Rhino Biotech Limited by market ranking:
- CLUS (PINK:CLUS): Ranked #1968 globally with a market cap of $8.00 Billion USD.
- Cartesian Growth Corporation II Warrant (NASDAQ:RENEW): Ranked #8546 globally with a market cap of $736.93 Million USD.
- Nh Special Purpose Acquisition 14 Co. Ltd (KQ:319400): Ranked #8994 globally with a market cap of $660.01 Million USD ( ₩966.39 Billion KRW).
- EQV Ventures Acquisition Corp. II (NYSE:EVAC): Ranked #10613 globally with a market cap of $465.51 Million USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #1968 | CLUS | PINK:CLUS | $8.00 Billion | $200.00 |
| #8546 | Cartesian Growth Corporation II Warrant | NASDAQ:RENEW | $736.93 Million | $138.87 |
| #8994 | Nh Special Purpose Acquisition 14 Co. Ltd | KQ:319400 | $660.01 Million | ₩30450.00 |
| #10613 | EQV Ventures Acquisition Corp. II | NYSE:EVAC | $465.51 Million | $10.07 |
Rhino Biotech Limited Historical Marketcap From 2015 to 2024
Between 2015 and today, Rhino Biotech Limited's market cap moved from $186.29K to $ 3.10K, with a yearly change of -32.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | $3.10K | 0.00% |
| 2023 | $3.10K | 0.00% |
| 2022 | $3.10K | -99.65% |
| 2021 | $891.09K | +1266.67% |
| 2020 | $65.20K | -47.50% |
| 2019 | $124.19K | +122.22% |
| 2018 | $55.89K | -88.00% |
| 2017 | $465.73K | +552.17% |
| 2016 | $71.41K | -61.67% |
| 2015 | $186.29K | -- |
End of Day Market Cap According to Different Sources
On Nov 28th, 2025 the market cap of Rhino Biotech Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.10K USD |
| MoneyControl | $3.10K USD |
| MarketWatch | $3.10K USD |
| marketcap.company | $3.10K USD |
| Reuters | $3.10K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.